‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

It's a striking show of unity. Nine former senior officials from the US Department of Commerce spanning more than 20 years and five administrations—both Democratic and Republican—have joined forces to write to President Biden.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

Bayer irks High Court judge over £130k costs in refusing to produce document

9 January 2024 Judge says Bayer racked up high costs ‘in pursuit of vague point of principle’ | Teva and others wanted presentation slides as part of patent invalidity suit.

More features

From migraine drugs to COVID vaccine spats, US lawsuits pile up

How AI will be shaped by legal and regulatory developments in 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Merchant & Gould hires 13 attorneys to open new Boston office

Key EU and UK regulatory changes to watch for in 2026

PTAB year in review: A shifting landscape and outlook for 2026

From Edwards to Insulet: Three key medical device cases of 2025

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

More on this story

Editor's picks

Editor's picks

More features